Qu Biologics Discovers Correlation Between Patient Genetics and Response to Immunotherapy in Inflammatory Bowel Disease
03. März 2017 15:39 ET
|
Qu Biologics
VANCOUVER, BRITISH COLUMBIA--(Marketwired - March 3, 2017) - Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs) that aim to "reboot" the body's...
Qu Biologics Publishes Promising Paper on Novel Treatment for Allergic Airway Disease
13. Oktober 2016 20:31 ET
|
Qu Biologics
VANCOUVER, BRITISH COLUMBIA--(Marketwired - Oct. 13, 2016) - Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs) that aim to "reboot" the body's...
Qu Biologics Closes Private Financing of CDN$4 Million
12. April 2016 11:30 ET
|
Qu Biologics
VANCOUVER, BRITISH COLUMBIA--(Marketwired - April 12, 2016) - Qu Biologics Inc., a biotechnology company developing Site Specific Immunomodulators (SSIs) that aim to restore the body's...
Qu Biologics Awarded Genome BC Funding to Study QBECO Site Specific Immunomodulator (SSI) for Ulcerative Colitis
06. April 2016 10:30 ET
|
Qu Biologics
VANCOUVER, BRITISH COLUMBIA--(Marketwired - April 6, 2016) - Qu Biologics Inc., a biotechnology company developing Site Specific Immunomodulators (SSIs) that aim to restore the body's...
Qu Biologics Announces Initial Results in Randomized, Placebo-Controlled Crohn's Disease Clinical Trial
21. März 2016 08:30 ET
|
Qu Biologics
VANCOUVER, BRITISH COLUMBIA--(Marketwired - March 21, 2016) - Qu Biologics Inc., an immunotherapy company developing Site Specific Immunomodulators (SSIs) for cancer and other inflammatory...
Qu Biologics Closes Oversubscribed Financing; Crohn's Disease Phase 2 Clinical Trial Results in First Quarter 2016
23. Dezember 2015 09:05 ET
|
Qu Biologics
VANCOUVER, BRITISH COLUMBIA--(Marketwired - Dec. 23, 2015) - Qu Biologics Inc., a biotechnology company developing Site Specific Immunomodulators (SSIs) that aim to restore the body's...
Qu Biologics Completes Enrollment of Randomized Clinical Trial in Crohn's Disease
24. November 2015 08:20 ET
|
Qu Biologics
VANCOUVER, BRITISH COLUMBIA--(Marketwired - Nov. 24, 2015) - Qu Biologics Inc., a biotechnology company developing Site Specific Immunomodulators (SSIs) that aim to restore normal immune...
Qu Biologics Granted Three New Patents for Treating Inflammatory Bowel Disease, Colon Cancer and Skin Cancer
17. November 2015 17:20 ET
|
Qu Biologics
VANCOUVER, BRITISH COLUMBIA--(Marketwired - Nov. 17, 2015) - Qu Biologics Inc., a biotechnology company developing Site Specific Immunomodulators (SSIs) that aim to restore normal immune...
Qu Biologics Granted U.S. Patent for Use of Staphylococcus Aureus-Based Immunotherapies to Treat Melanoma
29. September 2015 09:00 ET
|
Qu Biologics
VANCOUVER, BRITISH COLUMBIA--(Marketwired - Sept. 29, 2015) - Qu Biologics Inc., a biotechnology company developing Site Specific Immunomodulators (SSIs) that aim to restore normal immune...
Qu Biologics Opens Additional Ulcerative Colitis Clinical Trial Sites in Edmonton and Hamilton
31. August 2015 09:00 ET
|
Qu Biologics
VANCOUVER, BRITISH COLUMBIA--(Marketwired - Aug. 31, 2015) - Qu Biologics Inc., a biotechnology company developing Site Specific Immunomodulators (SSIs) that aim to restore normal immune...